Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00136747 · ClinicalTrials.gov registry record · Phase 1

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

A Phase 1 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target

NCT00136747 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00136747, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target

Study Summary

One of nicotine's effects on the body is at the level of the NMDA receptors in the brain. Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment of nicotine addiction. The purpose of this study is to evaluate the effectiveness of memantine using a laboratory model of tobacco addiction. The investigators will compare the effects of memantine with bupropion, medication currently used to facilitate smoking cessation.

Interventions

  • DRUG placebo
  • DRUG Memantine
  • DRUG bupropion

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2004-01
Est. Completion 2009-05
Phase Phase 1

What the Registry Record Tells You About NCT00136747

The ClinicalTrials.gov registry entry for NCT00136747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00136747 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00136747 about?

NCT00136747 is a clinical study titled "The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1". One of nicotine's effects on the body is at the level of the NMDA receptors in the brain. Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment of nicotine addiction. The purpose of this study is to evaluate the effectiveness of memantine using a laboratory mo...

What is the current status of trial NCT00136747?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2004-01. Estimated completion is 2009-05.

What interventions are being tested in trial NCT00136747?

The interventions under investigation include: placebo (DRUG), Memantine (DRUG), bupropion (DRUG).

Who is sponsoring clinical trial NCT00136747?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.